CCTG CO.26: Updated Analysis and Impact of Plasma-Detected Microsatellite Stability (MSS) and Tumor Mutation Burden (TMB) in a Phase II Trial of Durvalumab (D) Plus Tremelimumab (T) and Best Supportive Care (BSC) Versus BSC Alone in Patients (pts) with Refractory Metastatic Colorectal Carcinoma (Rmcrc).